Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 269 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| VistaGen Therapeutics Inc | VTGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.07 | 1.44% | 4.94 | 07:00:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.87 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 19 | 269 | - | 1.62 - 24.71 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:00:04 | 1 | $ 5.00 | USD |
VistaGen Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 131.6M | 27.02M | - | -227k | -59.25M | -2.19 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
VistaGen Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VTGN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.62 | 5.18 | 3.47 | 4.49 | 919,883 | 1.32 | 36.46% |
| 1 Month | 2.88 | 5.18 | 2.4501 | 3.67 | 743,365 | 2.06 | 71.53% |
| 3 Months | 6.09 | 6.23 | 2.4501 | 3.64 | 593,203 | -1.15 | -18.88% |
| 6 Months | 2.78 | 24.71 | 1.62 | 7.97 | 1,222,609 | 2.16 | 77.7% |
| 1 Year | 3.60 | 24.71 | 1.62 | 5.26 | 3,350,938 | 1.34 | 37.22% |
| 3 Years | 24.30 | 106.50 | 1.62 | 22.20 | 3,757,569 | -19.36 | -79.67% |
| 5 Years | 52.80 | 106.50 | 1.62 | 22.19 | 2,538,867 | -47.86 | -90.64% |
VistaGen Therapeutics Description
| Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression. |
